Prosecution Insights
Last updated: May 29, 2026
Application No. 17/908,819

PROCESS FOR MANUFACTURE OF A COMPLEXING AGENT

Final Rejection §112
Filed
Sep 01, 2022
Priority
Mar 03, 2020 — EU 20160695.1 +1 more
Examiner
STOCKTON, LAURA LYNNE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BASF Corporation
OA Round
2 (Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
1011 granted / 1348 resolved
+15.0% vs TC avg
Strong +34% interview lift
Without
With
+33.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
28 currently pending
Career history
1377
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
45.0%
+5.0% vs TC avg
§102
20.8%
-19.2% vs TC avg
§112
17.1%
-22.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1348 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-6, 8 and 9 are pending in the instant application. Objections and rejections made in the previous Office Action that do not appear below have been overcome by Applicant’s amendments to the specification and to the claims. Therefore, arguments pertaining to these objections and rejections will not be addressed. Response to Amendment The Declaration under 37 CFR 1.132 filed February 2, 2026 is sufficient to overcome the rejection of the claims based upon nonstatutory double patenting and the rejection of the claims under 35 USC 103. The following rejections are as a result of the current amendments to the claims filed February 2, 2026. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 4 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 4 is now confusing because of the phrase “the aqueous solution of step (a) and a solution of alkali metal hydroxide are simultaneously added to an aqueous solution of alkali metal hydroxide”. Currently amended claim 1 states that an alkali metal is absent in step (a). Therefore, claim 4 is indefinite. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 4 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 4 fails to further limit currently amended claim 1 because claim 4 is broader in scope than claim 1. Claim 4 states that “the aqueous solution of step (a) and a solution of alkali metal hydroxide are simultaneously added to an aqueous solution of alkali metal hydroxide”. However, currently amended claim 1 states that an alkali metal is absent in step (a). Allowable Subject Matter Claims 1-3, 5, 6, 8 and 9 are allowed. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to: Laura L. Stockton (571) 272-0710. The examiner can normally be reached on Monday-Friday from 8:30 am to 6 pm, Eastern Standard Time. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s acting supervisor, James Alstrum-Acevedo can be reached on 571/272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAURA L STOCKTON/ Primary Examiner, Art Unit 1626 Work Group 1620 Technology Center 1600 May 11, 2026 Book XXVII, page 89
Read full office action

Prosecution Timeline

Sep 01, 2022
Application Filed
Sep 10, 2025
Non-Final Rejection mailed — §112
Feb 02, 2026
Response Filed
Feb 02, 2026
Response after Non-Final Action
Apr 29, 2026
Examiner Interview (Telephonic)
May 13, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12624048
PHOTOCHROMIC CYCLIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC CYCLIC COMPOUND
3y 9m to grant Granted May 12, 2026
Patent 12623993
Synthesis of Vinyl Cyclobutyl Intermediates
3y 6m to grant Granted May 12, 2026
Patent 12612363
RECRYSTALLISATION OF 5-METHOXY-N,N-DIMETHYLTRYPTAMINE(5-MeODMT)
4y 4m to grant Granted Apr 28, 2026
Patent 12606562
PYRIDOPYRIMIDINES DERIVATIVES AS P2X3 INHIBITORS
4y 4m to grant Granted Apr 21, 2026
Patent 12606528
METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY
3y 11m to grant Granted Apr 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
99%
With Interview (+33.8%)
2y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1348 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month